The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPersimmon Regulatory News (PSN)

Share Price Information for Persimmon (PSN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,312.50
Bid: 1,312.50
Ask: 1,314.00
Change: 30.00 (2.34%)
Spread: 1.50 (0.114%)
Open: 1,296.00
High: 1,313.00
Low: 1,296.00
Prev. Close: 1,282.50
PSN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

CEO change

7 Nov 2018 07:00

RNS Number : 5936G
Persimmon PLC
07 November 2018
 

7 November 2018

 

Persimmon plc

("Persimmon" or "the Company")

 

Jeff Fairburn to step down as CEO

 

David Jenkinson to be appointed interim CEO

 

Persimmon plc announces today that by mutual agreement and at the request of the Company, Jeff Fairburn, Group Chief Executive, is to step down. Jeff has been a successful leader of the business since his appointment in 2013, but the Board believes that the distraction around his remuneration from the 2012 LTIP scheme continues to have a negative impact on the reputation of the business and consequently on Jeff's ability to continue in his role. 

 

David Jenkinson, currently Group Managing Director, will be appointed as interim Group Chief Executive and will assume his new role on 31 December 2018 and Jeff will leave the Company on that date. The Board has commenced a formal process to select a permanent successor.

 

David joined Persimmon in 1997 and was appointed to the Board in December 2013. He was appointed Group Managing Director in January 2016 and, working with Jeff, has played a central role in the development of the business. 

 

Roger Devlin, Persimmon's Chairman, said: "Under Jeff's leadership Persimmon has sold more than 74,000 homes across the UK while more than doubling in size, increasing its market capitalisation from £3.4 bn to £7.5 bn, returning over £2.2bn to shareholders and producing industry leading margins and returns on capital. However, given the continuing distraction around the scale of his remuneration resulting from the 2012 LTIP, the Board believes that it is now necessary for there to be to be a change of leadership. On behalf of the Board I would like to thank Jeff for his significant contribution to the business over a 29 year period.

 

"David is an experienced operator in the housebuilding sector and has made a significant contribution to Persimmon in a number of senior roles, particularly in land purchasing. I am grateful that he has agreed to take on the role of interim CEO."

 

Jeff Fairburn said: "It has been an honour to lead Persimmon through an exciting period of development. I had hoped that revealing my plans to create a charitable trust and to waive a proportion of the award would enable the Company to put the issue of the 2012 LTIP behind it. However, this has not been the case and so it is clearly now in the best interests of Persimmon that I should step down. I wish the Company the very best for the future."

 

Remuneration Arrangements

On 6 November 2018, Jeff and the Company agreed to the terms of a Settlement Agreement whereby his employment will end on 31 December 2018.

The arrangements in relation to Jeff's entitlement under the 2012 LTIP satisfy his contractual entitlement; the Remuneration Committee has not exercised any discretion in his favour.

Following the surrender of options announced on 23 February 2018, the second and final vest of all remaining options to all participants in the 2012 LTIP occurred in full on 2 July 2018.

The extension of the holding period applying to 50% of Jeff's remaining second vest shares (after payment of tax) included a requirement that Jeff not resign from employment with Persimmon and these shares were voluntarily pledged as security against his commitment to stay with the business (the "restricted" shares).

Whilst the Company has sought to mitigate the entitlement falling due to Jeff, as Jeff is leaving at the Company's request, legal advice has confirmed that the Company does not have any discretion to withhold or seek forfeiture over any of the "restricted" 2012 LTIP shares, although these continue to be required to be held until 6 July 2021.

The Company has agreed with Jeff to reduce his 12 month notice period and therefore there will be no further payments of salary or provision of benefits (including pension) after 31 December 2018. Jeff has no bonus entitlement for 2018 and no awards under any of the Company's share plans other than his deferred bonus share scheme awards and unvested SAYE options, which will lapse on departure.

David Jenkinson's remuneration terms will not change on his appointment to interim CEO.

 

The Company has today separately announced a scheduled trading update for the period from 1 July 2018 to 6 November 2018. 

 

Further details of the remuneration arrangements relating to Jeff's exit from the business have been included on the Company's corporate website in accordance with section 430(2B) of the Companies Act 2006.

 

This announcement contains inside information. 

 

Classification: Inside information

 

Further information, please contact:

Persimmon plc

Citigate Dewe Rogerson

Roger Devlin, Chairman

Simon Rigby / Kevin Smith

Tel: +44 (0)1904 642199

Tel: +44 (0)20 7638 9571

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
BOAFSFSMWFASEFF
Date   Source Headline
25th Apr 20242:09 pmRNSResult of AGM
25th Apr 20247:00 amRNSQ1 Trading Statement
2nd Apr 20241:49 pmRNSTotal Voting Rights
28th Mar 202412:53 pmRNSDirector/PDMR Shareholding
25th Mar 20244:47 pmRNSDirector/PDMR Shareholding
25th Mar 20242:07 pmRNSAnnual Report 2023 and Notice of AGM 2024
12th Mar 20241:38 pmRNSDirector/PDMR Shareholding
12th Mar 20247:00 amRNSFull Year Results
11th Jan 20246:00 pmRNSDechra Pharmaceuticals
10th Jan 20247:00 amRNSTrading Statement
1st Dec 20234:48 pmRNSBlock listing Interim Review
1st Dec 20234:45 pmRNSTotal Voting Rights
17th Nov 202310:25 amRNSHolding(s) in Company
8th Nov 20237:00 amRNSAppointment of Chief Financial Officer
7th Nov 20237:00 amRNSQ3 Trading Statement
3rd Nov 20231:15 pmRNSHolding(s) in Company
1st Sep 20231:15 pmRNSTotal Voting Rights
10th Aug 20237:04 amRNSHalf Year Results
27th Jul 202310:13 amRNSDirectorate Change
10th Jul 20239:27 amRNSDirector Declaration
3rd Jul 20232:46 pmRNSTotal Voting Rights
1st Jun 20234:38 pmRNSTR-1: Notification of major holdings
1st Jun 20231:07 pmRNSBlock listing Interim Review
1st Jun 202311:06 amRNSTotal Voting Rights
3rd May 20235:00 pmRNSHolding(s) in Company
3rd May 20234:12 pmRNSDirector/PDMR Shareholding
2nd May 202311:13 amRNSTotal Voting Rights
26th Apr 20234:32 pmRNSResult of AGM
26th Apr 20237:00 amRNSQ1 Trading Statement
3rd Apr 20234:01 pmRNSDirector/PDMR Shareholding
3rd Apr 20233:05 pmRNSTotal Voting Rights
27th Mar 20233:44 pmRNSDirector/PDMR Shareholding
22nd Mar 20233:00 pmRNSAnnual Report 2022 and Notice of AGM 2023
13th Mar 20231:57 pmRNSDirectorate Change
13th Mar 202312:19 pmRNSUK Government Self Remediation Contract Signed
7th Mar 20235:33 pmRNSHolding(s) in Company
7th Mar 20237:04 amRNSDirector Declaration
6th Mar 20235:02 pmRNSHolding(s) in Company
1st Mar 20237:00 amRNSFull Year Results
12th Jan 20237:00 amRNSTrading Statement
1st Dec 20225:30 pmRNSBLOCK LISTING SIX MONTHLY RETURN
1st Dec 20225:25 pmRNSVoting Rights and Capital
8th Nov 20227:00 amRNSTrading Statement
1st Nov 20221:00 pmRNSTotal Voting Rights
1st Nov 20229:24 amRNSHolding(s) in Company
10th Oct 20222:24 pmRNSDirector/PDMR Shareholding
5th Oct 202210:26 amRNSHolding(s) in Company
4th Oct 20223:07 pmRNSDirector/PDMR Shareholding
3rd Oct 20222:12 pmRNSTotal Voting Rights
22nd Sep 20223:54 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.